DOCSLIB.ORG

Lipolytic Enzyme. Uses Thereof in the Food Industry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lipolytic Enzyme. Uses Thereof in the Food Industry (19) & (11) EP 2 267 107 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.12.2010 Bulletin 2010/52 C11B 3/00 (2006.01) A23J 7/00 (2006.01) C12N 9/20 (2006.01) (21) Application number: 10174040.5 (22) Date of filing: 18.07.2005 (84) Designated Contracting States: • Soe, Jørn AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-8381, Tilst (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Mikkelsen, Jørn SK TR DK-2650, Hvidovre (DK) • Povelainen, Mira (30) Priority: 16.07.2004 GB 0416035 FIN-00360, Helsinki (FI) 26.07.2004 US 591185 P • Pitkanen, Virve 07.07.2005 GB 0513859 02320 Espoo (FI) (83) Declaration under Rule 32(1) EPC (expert (74) Representative: Williams, Aylsa solution) D Young & Co LLP 120 Holborn (62) Document number(s) of the earlier application(s) in London EC1N 2DY (GB) accordance with Art. 76 EPC: 05773820.5 / 1 776 455 Remarks: This application was filed on 25-08-2010 as a (71) Applicant: Danisco A/S divisional application to the application mentioned 1001 Copenhagen K (DK) under INID code 62. (72) Inventors: • Miasnikov, Andrei 10160 Degerby (FI) (54) Lipolytic Enzyme. Uses Thereof In The Food Industry (57) The invention also encompases theuse of a lipo- a galactolipid to one or more acyl acceptor substrates, lytic enzyme obtainable from one of the following genera: wherein the enzyme is obtainable fromSteptomyces Streptomyces, Corynebacterium and Thermobifida in species and includes a lipolytic enzyme comprising an various methods and uses, wherein said lipolytic enzyme amino acid sequence as shown in SEQ ID No. 4 or an is capable of hydrolysing a glycolipid or a phospholipid amino acid sequence which has at least 60% identity or transferring an acyl group from a glycolipid or phos- thereto. The enzyme may be encoded by a nucleic acid pholipids to a acyl acceptor. Preferably, the lipolytic en- selected from the group consisting of: zyme for use in these methods and uses comprises an a nucleic acid comprising a nucleotide sequence shown amino acid sequence as shown in any one of SEQ. ID. in SEQ ID No. 3; No.s 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence a nucleic acid which is related to the nucleotide sequence having at least 70% identity therewith or comprises a of SEQ ID No. 3 by the degeneration of the genetic code; nucleotide sequence shown as SEQ ID No. 3, 6, 9, 13, and 15 or 17 or a nulceotide seqeunce which has at least a nucleic acid comprising a nucleotide sequence which 70% identity therewith. The present invention also relates has at least 70% identity with the nucleotide sequence to a lipolytic enzyme capable of hydrolysing at least a shown in SEQ ID No. 3. galactolipid or capable of transferring an acyl group from EP 2 267 107 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 267 107 A2 Description FIELD OF INVENTION 5 [0001] The present invention relates to a novel lipolytic enzyme, in particular a novel lipolytic enzyme, and nucleotide sequences encoding same. The present invention also relates to methods of production of the novel lipolytic enzyme and to uses thereof. The present invention also relates to methods and uses of a lipolytic enzyme. TECHNICAL BACKGROUND 10 [0002] The beneficial use of lipolytic enzymes active on glycolipids in bread making was taught in EP 1 193 314. It was taught that the partial hydrolysis products the lysoglycolipids were found to have very high emulsifier functionality. However, the enzymes taught in EP 1 193 314 were also found to have significant non- selective activity on triglycerides which resulted in unnecessarily high free fatty acid. 15 [0003] A lipolytic enzyme from Fusarium oxysporum having phospholipase activity has been taught in EP 0 869 167. This lipolytic enzyme has high triacylglyceride hydrolysing (lipase) activity. This enzyme is now sold by Novozymes A/S (Denmark) as Lipopan F™. [0004] WO02/00852discloses five lipase enzymes and their encoding polynucleotides, isolated from Fusarium venena- tum, F. sulphureum, Aspergillus berkeleyanum, F. culmorum and F. solani. All five enzymes are described as having 20 triacylglycerol hydrolysing activity, phospholipase and galactolipase activity. [0005] Lipolytic enzyme variants, with specific amino acid substitutions and fusions, have been produced; some of which have an enhanced activity on the polar lipids compared to the wildtype parent enzymes. WO01/39602 describes such a variant, referred to as SP979, which is a fusion of theThermomyces lanuginosus lipase, and the Fusarium oxysporum lipase described in EP 0 869 167. This variant has been found to have a significantly high ratio of activity 25 on phospholipids and glycolipids compared to triglycerides. [0006] In WO02/094123 it was discovered that by selecting lipolytic enzymes which were active on the polar lipids (glycolipids and phospholipids) in a dough, but substantially not active on triglycerides or 1-mono-glycerides an improved functionality could be achieved. [0007] In co-pending PCT application number PCT/IB2005/000875, wild-type lipolytic enzymes having a higher ratio 30 of activity on polar lipids as compared with triglycerides are taught. However, this document does not teach lipolytic enzymes from Streptomyces, Thermobifida or Corynebacterium species. [0008] Prior to the present invention no lipolytic enzymes having activity or significant activity on glycolipids had been published from Streptomyces species. Likewise, no lipolytic enzymes having activity or significant activity on glycolipids had been published from Thermobifida species or Corynebacterium species. Although lipases, i.e. triacylglycerol hy- 35 drolysing enzymes, have been isolated from Streptomyces species (see Vujaklija et al Arch Microbiol (2002) 178: 124-130 for example), these enzymes have never been identified as having glycolipid hydrolysing activity. ASPECTS OF THE INVENTION 40 [0009] The present invention in predicated upon the seminal finding of a lipolytic enzyme having significant galactolipid activity from the genus Streptomyces. In particular the lipolytic enzyme from the genusStreptomyces has significant galactolipid hydrolysing activity and/or significant galactolipid acyltransferase activity, particularly when used in the methods and uses according to the present invention. [0010] In addition, the present invention in predicated upon the seminal finding that lipolytic enzymes from the genera 45 Thermobifida or Corynebacterium have significant galactolipid activity. In particular the lipolytic enzymes from the genera Thermobifida or Corynebacterium have significant galactolipid hydrolysing activity and/or significant galactolipid acyl- transferase activity, particularly when used in the methods and uses of the present invention. [0011] In a broad aspect the present invention relates to a lipolytic enzyme capable of hydrolysing at least glycolipids and/or capable of transferring an acyl group from at least a glycolipid to one or more acyl acceptor substrates, wherein 50 the enzyme is obtainable, preferably obtained, from Streptomyces species. [0012] In a further aspect the present invention relates to a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of: 55 a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence 2 EP 2 267 107 A2 shown in SEQ ID No. 3. [0013] The present invention yet further provides a lipolytic enzyme comprising an amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity thereto. 5 [0014] In another aspect the present invention provides a lipolytic enzyme capable of hydrolysing at least a galactolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme comprises an amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity thereto. [0015] In a further aspect the present invention provides a nucleic acid encoding a lipolytic enzyme comprising an 10 amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity therewith. [0016] SEQ ID No. 3 is shown in Figure 3 and SEQ ID No. 4 is shown in Figure 4. [0017] The present invention yet further provides a nucleic acid encoding a lipolytic enzyme, which nucleic acid is selected from the group consisting of: 15 a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 3. 20 [0018] The present invention yet further provides the use of a lipolytic enzyme according to the present invention in a substrate (preferably a foodstuff) for preparing a lysoglycolipid, for example digalactosyl monoglyceride (DGMG) or monogalactosyl monoglyceride (MGMG) by treatment of a glycolipid (e.g. digalactosyl diglyceride (DGDG) or monoga- lactosyl diglyceride (MGDG)) with the lipolytic enzyme according to the present invention to produce the partial hydrolysis 25 product, i.e. the lysoglycolipid. [0019] In a further aspect, the present invention provides the use of a lipolytic enzyme according to the present invention in a substrate (preferably a foodstuff) for preparing a lyso-phospholipid, for example lysolecithin, by treatment of a phospholipid (e.g.
Load more

Recommended publications
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,962,800 B2 Mathur Et Al
    USOO89628OOB2 (12) United States Patent (10) Patent No.: US 8,962,800 B2 Mathur et al. (45) Date of Patent: Feb. 24, 2015 (54) NUCLEICACIDS AND PROTEINS AND USPC .......................................................... 530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Naperville, IL (US) PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Nolling etal (J. Bacteriol. 183: 4823 (2001).* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 0 days. Isolates of Pseudomonas aeruginosa J. Bacteriol. (2003) 185: 1316-1325. (21) Appl. No.: 13/400,365 2002.Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (22) Filed: Feb. 20, 2012 bor New York, 2001, pp. 382-393. O O Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (65) Prior Publication Data toxicology” Toxicol. Lett. (2000) 1.12: 365-370. US 2012/O266329 A1 Oct. 18, 2012 * cited by examiner Related U.S. Application Data - - - Primary Examiner — James Martinell (62) Division of application No. 1 1/817,403, filed as (74) Attorney, Agent, or Firm — DLA Piper LLP (US) application No. PCT/US2006/007642 on Mar. 3, 2006, now Pat. No. 8,119,385. (57) ABSTRACT (60) Provisional application No. 60/658,984, filed on Mar. The invention provides polypeptides, including enzymes, 4, 2005.
    [Show full text]
  • The Role of Galactolipids in Spinach Chloroplast Lamellar Membranes: I
    Plant Physiol. (1974) 53, 699-704 The Role of Galactolipids in Spinach Chloroplast Lamellar Membranes I. PARTIAL PURIFICATION OF A BEAN LEAF GALACTOLIPID LIPASE AND ITS ACTION ON SUB- CHLOROPLAST PARTICLES" 2 Received for publication October 30, 1973 and in revised form January 3, 1974 MARK M. ANDERSON,' RICHARD E. MCCARTY, AND ELIZABETH A. ZIMMER Section of Biochemistry, Molecular and Cell Biology, Cornell University, Ithaca, New York 14850 ABSTRACT sis, such as fulfilling a structural requirement or even partici- pating directly in a reaction essential to photosynthesis. In an A galactolipid lipase has been isolated and partially purified effort to elucidate the possible role(s) of galactosyl diglycerides from the chloroplast fraction of the primary leaves of Phase- in photosynthesis, we isolated and partially purified a galacto- olus vulgaris var. Kentucky Wonder. The lipase hydrolyzed lipid lipase (galatosyl diglyceride acyl hydrolase) from primary monogalactosyl diglyceride rapidly and phosphatidyl choline bean leaf chloroplasts. The lipase was then used to deacylate relatively slowly. Triolein and p-nitrophenyl stearate were not the lipids in spinach chloroplasts and subchloroplast particles hydrolyzed. so that their ultrastructure and biochemical capabilities could Spinach subchloroplast particles were excellent substrates be determined as a function of galactolipid content. for the lipase. Initial rates of fatty acid release from sub- Galactolipase activity was first detected in extracts of Pha- chloroplast particles at 30 C by the lipase as high as 60 micro- seolus multifloris primary leaves by Sastry and Kates (19). equivalents per minute per milligram protein were observed. More recently Helmsing (9) has reported the purification of a At completion of the reaction, about 2.7 microequivalents of galactolipase from bean leaf homogenates.
    [Show full text]
  • Microalgal Enzymes with Biotechnological Applications
    marine drugs Review Microalgal Enzymes with Biotechnological Applications Giorgio Maria Vingiani 1, Pasquale De Luca 2 , Adrianna Ianora 1, Alan D.W. Dobson 3,4 and Chiara Lauritano 1,* 1 Marine Biotechnology Department, Stazione Zoologica Anton Dohrn, CAP80121 (NA) Villa Comunale, Italy 2 Research Infrastructure for Marine Biological Resources Department, Stazione Zoologica Anton Dohrn, CAP80121 (NA) Villa Comunale, Italy 3 School of Microbiology, University College Cork, College Road, T12 YN60 Cork, Ireland 4 Environmental Research Institute, University College Cork, Lee Road, T23XE10 Cork, Ireland * Correspondence: [email protected]; Tel.: +39-081-5833221 Received: 4 July 2019; Accepted: 1 August 2019; Published: 5 August 2019 Abstract: Enzymes are essential components of biological reactions and play important roles in the scaling and optimization of many industrial processes. Due to the growing commercial demand for new and more efficient enzymes to help further optimize these processes, many studies are now focusing their attention on more renewable and environmentally sustainable sources for the production of these enzymes. Microalgae are very promising from this perspective since they can be cultivated in photobioreactors, allowing the production of high biomass levels in a cost-efficient manner. This is reflected in the increased number of publications in this area, especially in the use of microalgae as a source of novel enzymes. In particular, various microalgal enzymes with different industrial applications (e.g., lipids and biofuel production, healthcare, and bioremediation) have been studied to date, and the modification of enzymatic sequences involved in lipid and carotenoid production has resulted in promising results. However, the entire biosynthetic pathways/systems leading to synthesis of potentially important bioactive compounds have in many cases yet to be fully characterized (e.g., for the synthesis of polyketides).
    [Show full text]
  • Chandran Et Al. Supporting Info.Pdf
    Supporting Information (SI) Appendix Part 1. Impact of tissue preparation, LMD, and RNA amplification on array output. p. 2 Text S1: Detailed Experimental Design and Methods Figure S1A: Correlation analysis indicates tissue preparation has minimal impact on ATH1 array output. Figure S1B: Correlation analysis indicates RNA degradation does not significantly impact array output. Figure S1C: Correlation analysis indicates two-round amplification does not significantly impact array output. Figure S1D: Independent biological replicates of LMD samples are highly correlated. Figure S1E: Validation of LMD array expression by qPCR. Table S1: Tissue preparation-associated genes Part 2. Analysis of LMD and parallel whole leaf array data. p. 13 Table S2A: Known PM-impacted genes enriched in LMD dataset Table S2B: Dataset of LMD and whole leaf genes with PM-altered expression Table S2C: LMD PM MapMan Results and Bins Table S2D: ics1 vs. WT LMD PM MapMan Results and Bins Table S2E: Infection site-specific changes for redox and calcium categories Table S2F: cis-acting regulatory element motif analysis Part 3. Process network construction p. 149 3A. Photosynthesis 3B. Cold/dehydration response Part 4. Powdery mildew infection of WT and myb3r4 mutants p. 173 Text S4: Detailed Experimental Design and Methods (supplement to manuscript) Figure S4A. Uninfected 4 week old WT and myb3r4 plants Figure S4B. myb3r4 mutants exhibit reduced visible PM growth and reproduction Figure S4C. PM-infected WT and myb3r4 mutants do not exhibit cell death Figure S4D. Endoreduplication occurs at site of PM infection not distal to infection Figure S4E. Ploidy correlates with nuclear size. Part 1. Impact of tissue preparation, LMD, and RNA amplification on array output.
    [Show full text]
  • And Fe(II)-Dependent Oxygenase Superfamily Protein(AT4G10500)
    AGI code Name At4g10500 2-oxoglutarate (2OG) and Fe(II)-dependent oxygenase superfamily protein(AT4G10500) GOTERM_BP_DIRECT defense response to oomycetes, response to oomycetes, response to bacterium, response to fungus, response to salicylic acid, leaf senescence, secondary metabolic process, salicylic acid catabolic process, oxidation-reduction process, GOTERM_MF_DIRECT oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors, metal ion binding, dioxygenase activity, At5g59540 2-oxoglutarate (2OG) and Fe(II)-dependent oxygenase superfamily protein(AT5G59540) GOTERM_BP_DIRECT oxidation-reduction process, GOTERM_CC_DIRECT cytoplasm, GOTERM_MF_DIRECT oxidoreductase activity, metal ion binding, dioxygenase activity, At3g55090 ABC-2 type transporter family protein(ABCG16) GOTERM_BP_DIRECT pollen wall assembly, GOTERM_CC_DIRECT plasma membrane, integral component of membrane, GOTERM_MF_DIRECT ATP binding, ATPase activity, coupled to transmembrane movement of substances, At2g37360 ABC-2 type transporter family protein(ABCG2) GOTERM_BP_DIRECT transport, suberin biosynthetic process, GOTERM_CC_DIRECT plasma membrane, integral component of membrane, GOTERM_MF_DIRECT ATP binding, ATPase activity, ATPase activity, coupled to transmembrane movement of substances, At3g47780 ABC2 homolog 6(ABCA7) GOTERM_BP_DIRECT lipid transport, GOTERM_CC_DIRECT plasma membrane, plasmodesma, integral component of membrane, intracellular
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii
    POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii http://rcin.org.pl WSKAZÓWKI DLA AUTORÓW Kwartalnik „Postępy Biochemii” publikuje artykuły monograficzne omawiające wąskie tematy, oraz artykuły przeglądowe referujące szersze zagadnienia z biochemii i nauk pokrewnych. Artykuły pierwszego typu winny w sposób syntetyczny omawiać wybrany temat na podstawie możliwie pełnego piśmiennictwa z kilku ostatnich lat, a artykuły drugiego typu na podstawie piśmiennictwa z ostatnich dwu lat. Objętość takich artykułów nie powinna przekraczać 25 stron maszynopisu (nie licząc ilustracji i piśmiennictwa). Kwartalnik publikuje także artykuły typu minireviews, do 10 stron maszynopisu, z dziedziny zainteresowań autora, opracowane na podstawie najnow­ szego piśmiennictwa, wystarczającego dla zilustrowania problemu. Ponadto kwartalnik publikuje krótkie noty, do 5 stron maszynopisu, informujące o nowych, interesujących osiągnięciach biochemii i nauk pokrewnych, oraz noty przybliżające historię badań w zakresie różnych dziedzin biochemii. Przekazanie artykułu do Redakcji jest równoznaczne z oświadczeniem, że nadesłana praca nie była i nie będzie publikowana w innym czasopiśmie, jeżeli zostanie ogłoszona w „Postępach Biochemii”. Autorzy artykułu odpowiadają za prawidłowość i ścisłość podanych informacji. Autorów obowiązuje korekta autorska. Koszty zmian tekstu w korekcie (poza poprawieniem błędów drukarskich) ponoszą autorzy. Artykuły honoruje się według obowiązujących stawek. Autorzy otrzymują bezpłatnie 25 odbitek swego artykułu; zamówienia na dodatkowe odbitki (płatne) należy zgłosić pisemnie odsyłając pracę po korekcie autorskiej. Redakcja prosi autorów o przestrzeganie następujących wskazówek: Forma maszynopisu: maszynopis pracy i wszelkie załączniki należy nadsyłać w dwu egzem­ plarzach. Maszynopis powinien być napisany jednostronnie, z podwójną interlinią, z marginesem ok. 4 cm po lewej i ok. 1 cm po prawej stronie; nie może zawierać więcej niż 60 znaków w jednym wierszu nie więcej niż 30 wierszy na stronie zgodnie z Normą Polską.
    [Show full text]
  • Unraveling the ORE1 Regulon in Arabidopsis Thaliana : Molecular
    Max Planck-Institut für Molekulare Pflanzenbiologie und Universität Potsdam Arbeitsgruppe Prof. Dr. Bernd Mueller-Roeber Unraveling the ORE1 Regulon in Arabidopsis thaliana: Molecular and Functional Characterization of Up- and Down-stream Components Dissertation zur Erlangung des akademischen Grades “doctor rerum naturalium” (Dr. rer. nat.) in der Wissenschaftsdisziplin “Molekularbiologie” eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät der Universität Potsdam von Lilian Paola Matallana-Ramírez Potsdam, den 11.04.2012 Published online at the Institutional Repository of the University of Potsdam: URL http://opus.kobv.de/ubp/volltexte/2012/6264/ URN urn:nbn:de:kobv:517-opus-62646 http://nbn-resolving.de/urn:nbn:de:kobv:517-opus-62646 Lilian Paola Matallana-Ramírez Dedicated to my beloved deceased grandma Graciela “-Try not to become a man of success but rather to become a man of value”. A. Einstein ii Contents Summary Leaf senescence is an active process required for plant survival, and it is flexibly controlled, allowing plant adaptation to environmental conditions. Although senescence is largely an age-dependent process, it can be triggered by environmental signals and stresses. Leaf senescence coordinates the breakdown and turnover of many cellular components, allowing a massive remobilization and recycling of nutrients from senescing tissues to other organs (e.g., young leaves, roots, and seeds), thus enhancing the fitness of the plant. Such metabolic coordination requires a tight regulation of gene expression. One important mechanism for the regulation of gene expression is at the transcriptional level via transcription factors (TFs). The NAC TF family (NAM, ATAF, CUC) includes various members that show elevated expression during senescence, including ORE1 (ANAC092/AtNAC2) among others.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]